UBS O'Connor’s Outlook Therapeutics OTLK Stock Holding History

UBS O'Connor’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-36,000	Closed	-$266K	–	581
2024 Q2	$266K	Buy	+36,000	New	+$289K	0.01%	405

Other funds holding OTLK

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

UBS O'Connor's OTLK Position: Q3 2024 in Review

UBS O'Connor sold out of Outlook Therapeutics (OTLK) in Q3 2024, closing a stake of 36,000 shares — an estimated $266K sold.

UBS O'Connor first reported a position in OTLK in Q2 2024 and held it in 1 quarter. The position peaked at $266K in Q2 2024. 66 funds tracked by Wall St. Rank hold OTLK as of Q3 2024.

UBS O'Connor reported no remaining Outlook Therapeutics position as of Q3 2024 after selling out during the quarter.
UBS O'Connor sold 36,000 Outlook Therapeutics shares in Q3 2024, an estimated $266K.
UBS O'Connor first reported a position in Outlook Therapeutics in Q2 2024 and held it in 1 quarter.
UBS O'Connor's Outlook Therapeutics position peaked at $266K in Q2 2024.
66 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2024.

Based on UBS O'Connor's 13F filing for Q3 2024, filed 14 Nov 2024.